EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nootkatone Alleviates Type 2 Diabetes in db/db Mice Through AMPK Activation and ERK Inhibition: An Integrated In Vitro and In Vivo Study

Yingjie Li iD, Linlin Zheng, Mimi Chen, Ruodi Li, Yansu Yu, Lu Qiao, Jialu Liu, Xiaopo Zhang, Yong Zhang, Yuxin Zhang, Wei Zheng

Molecules · 2025

DOI: 10.3390/molecules30102111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Yingjie Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Harbin University of Commerce, Harbin 150028, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Polycyclic Sesquiterpenes, AMP-Activated Protein Kinases, MAP Kinase Signaling System. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Hainan provincial Nature Science Foundation of China, the Hainan provincial Key Research and Development Projects, the Nature Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 diabetes mellitus (T2DM) is a common chronic metabolic disorder that imposes a substantial healthcare burden globally. Recent advances highlight the potential of natural products in ameliorating T2DM. In this study, we investigated the therapeutic efficacy of nootkatone (Nok), a natural sesquiterpene ketone, in T2DM and elucidated its underlying mechanisms. In vivo experiments demonstrated that Nok administration markedly improved dysregulated glucose metabolism and ameliorated serum biochemical abnormalities in db/db mice. Leveraging a network pharmacology-based approach, we identified putative molecular targets of Nok. Subsequent in vitro analyses revealed that Nok significantly enhanced glucose consumption in cultured cells. Mechanistically, Nok robustly activated AMP-activated protein kinase (AMPK) while suppressing mitogen-activated protein kinase (MAPK) signaling. Western blot validation further indicated that Nok downregulated the phosphorylation of MAPK1/3 (ERK2/1), attenuating MAPK pathway activation and thereby alleviating metabolic dysfunction-associated fatty liver disease (MAFLD) progression in the diabetic model. Collectively, our findings suggest that Nok exerts anti-diabetic effects via dual modulation of AMPK activation and MAPK inhibition, effectively restoring metabolic homeostasis and mitigating inflammation in T2DM. This study positions Nok as a promising natural compound for therapeutic intervention in T2DM and associated metabolic disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Polycyclic SesquiterpenesAMP-Activated Protein KinasesMAP Kinase Signaling SystemHypoglycemic AgentsDiabetes Mellitus, ExperimentalSesquiterpenesAnimalsMiceHumansMaleDisease Models, AnimalGlucoseEnzyme Activation

Stichwörter der Autor:innen

db/db micediabeteslivernetwork pharmacologynootkatonepancreatic

Substanzen

Polycyclic SesquiterpenesAMP-Activated Protein KinasesnootkatoneHypoglycemic AgentsGlucoseSesquiterpenes

Autor:innen und Institutionen

  • School of Pharmacy, Harbin University of Commerce, Harbin 150028, China.
  • Department of Pharmacology, College of Basic Medicine and Life Sciences, Hainan Medical College, Haikou 571199, China.
  • Hainan Academy of Medical Sciences, Haikou 571199, China.
  • School of Pharmacy, Hainan Medical College, Haikou 571199, China.

ORCID-Profile: Yingjie Li

Förderung

  • The Hainan provincial Nature Science Foundation of China
  • the Hainan provincial Key Research and Development Projects
  • the Nature Science Foundation of China
  • the Project Supported by the Hainan Province Clinical Medical Center
  • the Excellent Talent Team of Hainan Province
  • the College Students' Innovative Entrepreneurial Training Plan Program
  • Hainan provincial Nature Science Foundation of China
  • Hainan provincial Key Research and Development Projects

Zitieren

APA

Li, Y., Zheng, L., Chen, M., Li, R., Yu, Y., Qiao, L., Liu, J., Zhang, X., Zhang, Y., Zhang, Y., & Zheng, W. (2025). Nootkatone Alleviates Type 2 Diabetes in db/db Mice Through AMPK Activation and ERK Inhibition: An Integrated In Vitro and In Vivo Study. Molecules. https://doi.org/10.3390/molecules30102111

Vancouver

Li Y, Zheng L, Chen M, Li R, Yu Y, Qiao L, et al. Nootkatone Alleviates Type 2 Diabetes in db/db Mice Through AMPK Activation and ERK Inhibition: An Integrated In Vitro and In Vivo Study. Molecules. 2025. doi:10.3390/molecules30102111

BibTeX
@article{Li2025,
  author = {Li, Yingjie and Zheng, Linlin and Chen, Mimi and Li, Ruodi and Yu, Yansu and Qiao, Lu and Liu, Jialu and Zhang, Xiaopo and Zhang, Yong and Zhang, Yuxin and Zheng, Wei},
  title = {Nootkatone Alleviates Type 2 Diabetes in db/db Mice Through AMPK Activation and ERK Inhibition: An Integrated In Vitro and In Vivo Study},
  journal = {Molecules},
  year = {2025},
  doi = {10.3390/molecules30102111}
}
Kostenlos starten →